Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 3 Trial of Odevixibat in Alagille Syndrome
jRCT2041240037Phase 3Active, not recruiting
- Sponsor
- Jadeite Medicines
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of odevixibat in Alagille syndrome (ALGS), sponsored by Jadeite Medicines. Primary endpoints: Change from baseline in scratching to Month 6, Change in serum bile acid levels and 1 more. Started Jul 2024; status: active, not recruiting.
02
Drugs
odevixibat
03
Conditions
Alagille syndrome (ALGS)
Beyond the preview
Go deeper on jRCT2041240037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240037.